MoFo Advises Adicet Bio on $80M Series B Financing

10/08/2019

Jim Krenn, Jay de Groot, Brennen Thomas Brodersen, and Kevin M. McKenna

Corporate, Emerging Companies + Venture Capital, and Life Sciences + Healthcare

MoFo News Item

Morrison & Foerster advised biopharmaceutical company Adicet Bio, Inc. in connection with the completion of its $80 million Series B financing, announced on October 2, 2019.

Adicet Bio focuses on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells and intends to use the financing to continue developing its proprietary technology, to enter the clinic in Non-Hodgkin's Lymphoma, and to advance its solid tumor programs.

The MoFo deal team was led out of San Diego by corporate partners Jim Krenn and Jay de Groot, and included associates Brennen Brodersen and Kevin McKenna.

Read the related press release.

 

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.